Scintigraphy Study to Evaluate the Gastrointestinal Behavior of EDP1815 Oral Dosage Forms
Status:
Recruiting
Trial end date:
2022-02-15
Target enrollment:
Participant gender:
Summary
This study is to find out how different types of capsules or tablets containing EDP1815 move
through the GI tract and release the drug after being swallowed. The capsules and tablets
also contain a very small dose of a commonly used radioactive label called technetium-99m
which is released in the GI tract to be seen on pictures taken by a scanner (gamma
scintigraphy).